Alexza News Elates Investors

Shares soared Monday after the company announced favorable study results for its treatment for migraines

Alexza Pharmaceuticals (ALXA) announced encouraging results on Mar. 26 from two studies intended to develop new treatments for migraine victims and schizophrenic patients with acute agitation. The Palo Alto (Calif.) company, which went public in spring 2006, is trying to come up with drugs that patients can inhale instead of receiving with the use of needles.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.